Mild renal disease increases major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting

• References

• 1 Manzano-Fernández S, Cambronero F, Caro-Martínez C. et al. Mild Kidney Disease is a Risk Factor for Major Bleeding in Patients with Atrial Fibrillation Undergoing Percutaneous coronary stenting. Thromb Haemost 2012; 107: 51-58.
• 2 Manoukian S, Feit F, Mehran R. et al. Impact of major bleeding on 30-Day mortality and clinical outcomes in patients with acute coronary syndromes: analysis from the ACUITY trial. JACC 2007; 49: 1362-1368.
• 3 De Caterina R, Connolly S, Chrolavicius S. et al. on behalf of the ACTIVE Investigators. Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. Eur Heart J 2010; 31: 2133-2140.
• 4 Marinigh R, Lane DA, Lip GY.. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and bleeding risk. J Am Coll Cardiol 2011; 57: 1339-1348.
• 5 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
• 6 To AC, Yehia M, Collins JF.. Atrial fibrillation in Haemodialysis patients: do the guidelines for anticoagulation apply?. Nephrology 2007; 12: 441-447.
• 7 Fang MC, Go AS, Chang Y. et al. A new risk scheme to predict warfarin-associated hemorrhage. JACC 2011; 58: 395-401.
• 8 Lip GY, Huber K, Anderotti F. et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28. [Erratum in Thromb Haemost 2010; 104: 653.]
• 9 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patient with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106: 569-579.
• 10 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
• 11 Alexander J, Lopes R, James S. et al. for the APPRAISE-2 Investigators. Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. N Engl J Med 2011; 365: 699-708.